Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations

Hanif Esmail, Frank Cobelens, Delia Goletti

Source: Eur Respir J, 55 (3) 1901957; 10.1183/13993003.01957-2019

Journal Issue: March

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Hanif Esmail, Frank Cobelens, Delia Goletti. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. Eur Respir J, 55 (3) 1901957; 10.1183/13993003.01957-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease Source: Eur Respir J, 52 (4) 1800946; 10.1183/13993003.00946-2018 Year: 2018
Evaluation of new biomarkers for laboratory diagnosis of tuberculosis Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools Year: 2018
Novel biomarker more strongly associated with tuberculosis treatment outcome than conventional or genotypic methods Source: International Congress 2015 – Science and biomarkers in TB Year: 2015
COVID-19 vaccines: immunology, regulation and clinical management Source: Eur Respir Monogr 2021; 94: 244-260 Year: 2021
Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis Source: Eur Respir J 2016; 48: 1751-1763 Year: 2016
T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation Source: Eur Respir J, 51 (3) 1800153; 10.1183/13993003.00153-2018 Year: 2018
Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016
Predicting the course of sarcoidosis with clinical factors Source: Eur Respir J 2005; 26: Suppl. 49, 32s Year: 2005
Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021
Clinical phenotyping: role in treatment decisions in sarcoidosis Source: Eur Respir Rev, 29 (155) 190145; 10.1183/16000617.0145-2019 Year: 2020
Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016
Inflammatory pathways in COPD. What we know and potential clinical implications Source: Annual Congress 2008 - New insights into COPD pathophysiology Year: 2008
Latest insights and challenges in tuberculosis vaccine development Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019
The disease model: implications for clinical practice Source: Eur Respir J, 51 (4) 1800188; 10.1183/13993003.00188-2018 Year: 2018